Testimony to the FDA Drug Safety and Risk Management Advisory Committee on the Restrictions on the Use of Lotronex

View as PDF.

Public Citizen recommends that restrictions on Lotronex (alosetron) be tightened, rather than loosened, due to its high risk of life-threatening adverse reactions compared with its marginal benefits.